Adrenosteriod composition and method for the treatment of shock by infusional therapy
AssigneeHepar Industries, Inc.
InventorFernando F. Fussi
Life of this patent
Estimating the term…
Abstract
Septic shock and other forms of shock are effectively treated using a blend of 18 different adrenosteroids in their physiologic ratios based upon an animal cortex extract as a model. The blend preferably administered by infusion to a person suffering from shock. The blend is more effect and at a lower dosage level than hydrocortisone base or water-soluble derivatives of hydrocortisone.
Claims11
A pharmaceutical composition consisting essentially, in percent by weight, of the following adrenosteroids:
- ______________________________________ 1. 11-Dehydrocorticosterone 10.0 .+-. 1.5 2. Corticosterone 18.5 .+-. 2.5 3. 11-Deoxy-17-hydroxycorticosterone 3.0 .+-. 0.5 4. Cortisone 14.0 .+-. 2.0 5. Hydrocortisone 23.0 .+-. 3.5 6. 4-Pregnene-5 and/or 20,21-diol or 2.0 .+-. 0.5 triol-3,11-dione 7. 4-Pregnene-5,17.alpha.,20.beta.,21-triol or 2.0 .+-. 0.5 tetrol-3,11-dione 8. 4-Pregnene-5,11.beta.,17.alpha.,20.beta.,21-tetrol-3-one 3.0 .+-. 0.5 9. 3.alpha. or .beta.,21-Dihydroxy-5.alpha. or .beta.-pregnane- 2.5 .+-. 0.5 11,20-dione 10. 3.alpha. or .beta.,11.beta.,21-Trihydroxy-5.alpha. or 3.0 .+-. 0.5 .beta.-pregnan-20-one 11. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnan-20-one 12. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.4 .+-. 0.5 .beta.-pregnane-11,20-dione 13. 3.alpha. or .beta.,17,21-Tetrahydroxy-20-oxo-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnane 14. Allopregnane-3.beta.,17.alpha.,20.beta.-21-tetrol 2.0 .+-. 0.5 15. Allopregnane-3.beta.,11.beta.,17.alpha.,20.beta.,21-pentol 2.0 .+-. 0.5 16. Deoxycorticosterone 3.0 .+-. 0.5 17. 18-Hydroxy-deoxycorticosterone 1.5 .+-. 0.3 18. Aldosterone 3.0 .+-. 0.5 ______________________________________
- together with a pharmaceutically acceptable carrier or diluent.
A method of treating the effects of shock comprising administering to a mammal suffering therefrom a symptom ameliorating amount of a pharmaceutical composition consisting essentially, in percent by weight of:
- ______________________________________ 1. 11-Dehydrocorticosterone 10.0 .+-. 1.5 2. Corticosterone 18.5 .+-. 2.5 3. 11-Deoxy-17-hydroxycorticosterone 3.0 .+-. 0.5 4. Cortisone 14.0 .+-. 2.0 5. Hydrocortisone 23.0 .+-. 3.5 6. 4-Pregnene-5 and/or 20,21-diol or 2.0 .+-. 0.5 triol-3,11-dione 7. 4-Pregnene-5,17.alpha.,20.beta.,21-triol or 2.0 .+-. 0.5 tetrol-3,11-dione 8. 4-Pregnene-5,11.beta.,17.alpha.,20.beta.,21-tetrol-3-one 3.0 .+-. 0.5 9. 3.alpha. or .beta.,21-Dihydroxy-5.alpha. or .beta.-pregnane- 2.5 .+-. 0.5 11,20-dione 10. 3.alpha. or .beta.,11 ,21-Trihydroxy-5.alpha. or 3.0 .+-. 0.5 .beta.-pregnan-20-one 11. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnan-20-one 12. 3.alpha. or .beta.,17,21-Trihydroxy-5.alpha. or 2.4 .+-. 0.5 .beta.-pregnane-11,20-dione 13. 3.alpha. or .beta.,17,21-Tetrahydroxy-20-oxo-5.alpha. or 2.5 .+-. 0.5 .beta.-pregnane 14. Allopregnane-3.beta.,17.alpha.,20.beta.-21-tetrol 2.0 .+-. 0.5 15. Allopregnane-3.beta.,11.beta.,17.alpha.,20.beta.,21-pentol 2.0 .+-. 0.5 16. Deoxycorticosterone 3.0 .+-. 0.5 17. 18-Hydroxy-deoxycorticosterone 1.5 .+-. 0.3 18. Aldosterone 3.0 .+-. 0.5 ______________________________________
Dependencies are inferred from the claim text.